Bell Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Bell Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$1K	Buy	+55	New	+$1.03K	﹤0.01%	1583

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OMS

Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DOFI

DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bell Investment Advisors's RXRX Position: Q4 2021 in Review

Bell Investment Advisors opened a new position in Recursion Pharmaceuticals (RXRX) in Q4 2021: 55 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1583 among its holdings.

126 funds tracked by Wall St. Rank hold RXRX as of Q4 2021.

Bell Investment Advisors held 55 shares of Recursion Pharmaceuticals worth $1K as of Q4 2021.
Recursion Pharmaceuticals was a new Bell Investment Advisors position in Q4 2021.
Recursion Pharmaceuticals made up ﹤0.01% of Bell Investment Advisors's portfolio in Q4 2021, its #1583 holding.
126 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2021.

Based on Bell Investment Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.